-

09:21:19 PM

EVAX Stock News

EVAX - Evaxion Biotech A/S

11/17/22 6:59 AM

Nasdaq : EVAX

clinical triallow float

Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced promising clinical data from the Phase 1/2a first-in-human

RHEA-AI

neutral

11/14/22 7:13 AM

Nasdaq : EVAX

earningslow float

Evaxion Announces Third Quarter 2022 Financial Results and Business Update

Per Norlén , M.D., PhD. joined Evaxion as Chief Executive Officer in October Enrollment of the first patient in our global Phase 2b clinical trial of EVX-01 Increased strategic focus on clinical lead oncology assets and partnering Cash and cash equivalents of $17.9 million sufficient to fund

RHEA-AI

very positive

11/10/22 4:09 AM

Nasdaq : EVAX

low float

Evaxion CEO comments on strategic focus

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that it intends to further increase its focus on its lead

RHEA-AI

neutral

10/18/22 5:00 AM

Nasdaq : EVAX

managementlow float

Abalos Therapeutics Appoints Thomas Bogenrieder as Chief Medical Officer

Dr. Bogenrieder will contribute more than 17 years of international clinical development experience including successfully guiding cancer immunotherapies through the clinical evaluation process. Prior to his role at Abalos, Dr. Bogenrieder served as Chief Clinical Officer for AMAL Therapeutics, where he oversaw the clinical development of cancer...

RHEA-AI

positive

10/05/22 8:32 AM

Nasdaq : EVAX

managementlow float

Evaxion welcomes Per Norlén as new CEO.

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announces that its new Chief Executive Officer (CEO) Per Norlén has joined

RHEA-AI

neutral

09/21/22 5:45 AM

Nasdaq : EVAX

low float

Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, reached an important milestone announcing today that it had enrolled its

RHEA-AI

positive

09/06/22 7:01 AM

Nasdaq : EVAX

low float

Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), announced today that the Company, in collaboration with UMass Chan Medical School (“UMass Chan”), has received a grant from the U.S. National Institutes of Health (“NIH”) for

RHEA-AI

positive

08/10/22 7:00 AM

Nasdaq : EVAX

earningslow float

Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update

Expanded DNA oncology vaccine program into non-small cell lung cancer, NSCLC Announced successful production of personalized cancer immunotherapies for melanoma Announced gonorrhea as second bacterial product target Ended second quarter with cash and cash equivalents of $25.3 million Evaxion will

RHEA-AI

neutral

08/02/22 7:00 AM

Nasdaq : EVAX

managementlow float

Evaxion Biotech A/S Announces Executive Management Changes

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced the following executive management changes. Lars Staal

RHEA-AI

neutral

07/29/22 5:46 PM

Nasdaq : EVAX

conferenceslow float

Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today that it will present its second-quarter 2022 financial

RHEA-AI

neutral

EVAX Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.evaxion-biotech.com
Security nameEvaxion Biotech A/S - ADR
Issue typead
SectorManufacturing
Sic code2836
Employees2021

About Evaxion Biotech A/S

Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus. or MRSA) induced skin and soft tissue infections.